Two thin strut drug-eluting stents (DES) are both non-inferior to a durable polymer DES, according to the BIO-RESORT Trial presented Oct. 30 at TCT 2016 and simultaneously published in The Lancet.

Clemens von Birgelen, MD, et al., conducted a multi-center, double-blinded, randomized trial to assess safety and efficacy of percutaneous coronary intervention using either thin strut biodegradable polymer stents (everolimus-eluting or sirolimus-eluting) or durable polymer zotarolimus-eluting stents. Of the 3,514 patients enrolled and analyzed, 2,449 had acute coronary syndromes, which included 1,073 ST-elevation myocardial infarctions. Twelve-month follow-up was available in 3,490 (99.3%) patients.

The results of the trial showed similar efficacy and safety between the thin strut biodegradable polymer stents and the durable polymer stent. The primary endpoint was met by 4.7 percent (55/1,172) of patients assigned to everolimus-eluting stents, 4.7 percent (55/1,169) assigned to sirolimus-eluting stents and 5.4 percent (63/1,173) assigned to zotarolimus-eluting stents.

According to von Birgelen, et al., “the absence of a loss of one-year safety and efficacy with the use of these biodegradable polymer-coated stents is a prerequisite before assessing their potential longer-term benefits.”

Keywords: Transcatheter Cardiovascular Therapeutics, Angina, Stable, Coronary Disease, Drug-Eluting Stents, Health Resorts, Percutaneous Coronary Intervention, Polymers, Stents, Drug-Eluting Stents

< Back to Listings